KenvueKVUE
About: Kenvue is the world's largest pure-play consumer health company by sales, generating $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio includes a wide array of some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and ever-changing consumer preferences, many of Kenvue's brands are the global leader in their respective segment thanks to their strong brand power.
Employees: 22,000
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
82% more call options, than puts
Call options by funds: $283M | Put options by funds: $156M
31% more first-time investments, than exits
New positions opened: 139 | Existing positions closed: 106
31% more repeat investments, than reductions
Existing positions increased: 426 | Existing positions reduced: 325
3% more funds holding
Funds holding: 948 [Q1] → 981 (+33) [Q2]
0.56% less ownership
Funds ownership: 98.69% [Q1] → 98.13% (-0.56%) [Q2]
12% less funds holding in top 10
Funds holding in top 10: 17 [Q1] → 15 (-2) [Q2]
16% less capital invested
Capital invested by funds: $40.5B [Q1] → $34.2B (-$6.35B) [Q2]
Research analyst outlook
10 Wall Street Analysts provided 1 year price targets over the past 3 months
10 analyst ratings
JP Morgan Andrea Teixeira 44% 1-year accuracy 17 / 39 met price target | 9%upside $25 | Overweight Maintained | 11 Oct 2024 |
Jefferies Keith Devas 0% 1-year accuracy 0 / 1 met price target | 18%upside $27 | Buy Initiated | 24 Sept 2024 |
RBC Capital Nik Modi 82% 1-year accuracy 18 / 22 met price target | 5%upside $24 | Sector Perform Downgraded | 24 Sept 2024 |
Piper Sandler Korinne Wolfmeyer 25% 1-year accuracy 6 / 24 met price target | 8%downside $21 | Neutral Maintained | 23 Sept 2024 |
JP Morgan Andrea Teixeira 44% 1-year accuracy 17 / 39 met price target | 5%upside $24 | Overweight Maintained | 7 Aug 2024 |
Financial journalist opinion
Based on 21 articles about KVUE published over the past 30 days
